Attached files
| file | filename |
|---|---|
| EX-3.1 - EXHIBIT 3.1 - Diffusion Pharmaceuticals Inc. | ex3-1.htm |
| EX-3.2 - EXHIBIT 3.2 - Diffusion Pharmaceuticals Inc. | ex3-2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
__________________
Date of Report (Date of earliest event reported): January 8, 2016
___________________
DIFFUSION PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
000-24477 |
30-0645032 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
2020 Avon Court, #4 Charlottesville, Virginia |
22902 |
|
(Address of principal executive offices) |
(Zip Code) |
(434) 220-0718
(Registrant’s telephone number, including area code)
RestorGenex Corporation
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.03 – Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On January 8, 2016, Diffusion Pharmaceuticals Inc. (formerly known as RestorGenex Corporation) (the “Company”) filed a Certificate of Amendment to its Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference. The Charter Amendment amended the Company’s Certificate of Incorporation to effect a change of the Company’s corporate name from “RestorGenex Corporation” to “Diffusion Pharmaceuticals Inc.” (the “Name Change”). The Name Change was approved by the Company’s board of directors on January 8, 2016.
In connection with the Name Change, the Company also amended its bylaws (the “Bylaws Amendment”) to reflect the new corporate name. A copy of the Bylaws Amendment is attached hereto as Exhibit 3.2 and is incorporated herein by reference.
Item 8.01 – Other Events
In connection with the Name Change, the new CUSIP number for the Company’s common stock is 253748 107.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits: |
|
Exhibit No. |
Description | |
|
3.1 |
Certificate of Amendment of the Certificate of Incorporation of Diffusion Pharmaceuticals Inc. (f/k/a RestorGenex Corporation), as filed with the Secretary of State of the State of Delaware on January 8, 2016. | |
|
3.2 |
Certificate of Amendment to Bylaws of Diffusion Pharmaceuticals Inc. (f/k/a RestorGenex Corporation), dated January 8, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: January 14, 2016 |
DIFFUSION PHARMACEUTICALS INC. |
| |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ David G. Kalergis |
|
|
|
Name: |
David G. Kalergis |
|
|
|
Title: |
Chief Executive Officer |
|